NDI-Lyso is a lysosome-targeted anticancer agent that induces the formation of rigid long fibers in cancer cell lysosomes through an enzyme-instructed self-assembly (EISA) mechanism catalyzed by cathepsin B. This process triggers lysosomal swelling, membrane permeabilization (LMP), and membrane disruption, ultimately leading to cancer cell apoptosis via a non-classical caspase-independent pathway. NDI-Lyso exhibits significant selective anticancer activity in various cancer cell lines and drug-resistant cancer cells (IC50 ~10 µM) while showing low toxicity to normal cells (IC50 > 60 µM)[1].
Molekulargewicht:
1469.69
CAS Nummer:
[2999646-19-2]
Formel:
C71H100N22O13
Target-Kategorie:
Apoptosis,Caspase
Anwendungsbeschreibung:
MCE Product type: Peptides
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
